HUTCHMED (China) HCM
NASDAQ HCM
$14.15 +0.02 (+0.14%)
At close: Sep 29, 2026 · 4:00 PM EDT

HUTCHMED (China) (HCM) Operating Leases (2019 - 2025)

Updated

HUTCHMED (China)'s Operating Leases was $2.88 million in the quarter ended Dec 31, 2025.

Analysis

HUTCHMED (China) (HCM) Operating Leases (2019 - 2025) Analysis & Trends

From the quarter ended Mar 31, 2019 onward, HUTCHMED (China) has reported Operating Leases for 12 quarters.

  • Operating Leases shows a five-year compound annual growth rate of -13.8% (years ended Dec 2020 to Dec 2025).
  • In earlier years, Operating Leases was $3.71 million in the year ended Dec 31, 2022 (-48.2%) and $7.16 million in the year ended Dec 31, 2021 (+18.1%).
  • The figure for the quarter ended Dec 31, 2025 marks the lowest quarterly Operating Leases since the quarter ended Jun 30, 2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 HUTCHMED (China) 2.47 Bn 2.48 Bn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 2.88 Mn
Jun 30, 2025 3.11 Mn
Dec 31, 2022 3.71 Mn
Dec 31, 2021 7.16 Mn
Jun 30, 2021 3.85 Mn
Mar 31, 2021 3.97 Mn
Dec 31, 2020 6.06 Mn
Jun 30, 2020 2.59 Mn
Dec 31, 2019 3.22 Mn
Sep 30, 2019 3.50 Mn
Jun 30, 2019 3.53 Mn
Mar 31, 2019 3.19 Mn
API Access

HUTCHMED (China) Operating Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-leases&ticker=HCM&period=max&api_key=YOUR_API_KEY